Chemical structure of lamivudine.
Find information on thousands of medical conditions and prescription drugs.

Lamivudine

Lamivudine (2',3'-dideoxy-3'-thiacytidine, 3TC) has the trade name EpivirĀ®. It is a potent reverse transcriptase inhibitor of the class nucleoside analog reverse transcriptase inhibitor (NARTI). more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Lamivudine has been used for treatment of chronic hepatitis B at a lower dose than for treatment of HIV. It improves the seroconversion of e-antigen positive hepatitis B and also improves histology staging of the liver. Long term use of lamivudine unfortunately leads to emergence of a resistant hepatitis B virus (YMDD) mutant. Despite this, lamivudine is still used widely as it is well tolerated.

History

Lamivudine was invented by Bernard Belleau and Nghe Nguyen-Ba at the Montreal-based IAF BioChem International, Inc. laboratories in 1989. The drug was later licensed to the British pharmaceutical company Glaxo for a 14 percent royalty.

Lamivudine was approved by the Food and Drug Administration (FDA) on Nov 17, 1995 for use with Zidovudine (AZT) and again in 2002 as a once-a-day dosed medication. The fifth antiretroviral drug on the market, it was the last NRTI for three years while the approval process switched to protease inhibitors. Its patent will expire in the United States on 2016-05-18.

Mechanism of action

Lamivudine is an analogue of cytidine. It can inhibit both types (1 and 2) of HIV reverse transcriptase and also the reverse transcriptase of hepatitis B. It needs to be phosphorylated to its triphosphate form before it is active. 3TC-triphosphate also inhibits cellular DNA polymerase.

Lamivudine is administered orally, and it is rapidly absorbed with a bio-availability of over 80%. Some research suggests that lamivudine can cross the blood-brain barrier. Lamivudine is often given in combination with zidovudine, with which it is highly synergistic. Lamivudine treatment has been shown to restore zidovudine sensitivity of previously resistant HIV. Several mutagenicity tests show that lamivudine should not show mutagenic activity in therapeutical doses.


Read more at Wikipedia.org


[List your site here Free!]


LAMIVUDINE - Epivir
From Research Initiative/Treatment Action!, 3/1/00

Lamivudine tablets are film-coated, white, and diamond-shaped with the dosage "150" imprinted on one side and "GX CJ7" on the other side. This drug is also available in a flavored solution or in combination with zidovudine in a tablet formulation called "Combivir."

"The discovery of lamivudine's hepatitis-suppressing potential will likely provide Glaxo with a needed boost, since the patent for the anti-ulcer drug Zantac, its No. I product, will soon expire."

Business Week 3526, p. 104, May 21, 1997

Also known as: 3TC

Background and description. Lamivudine received accelerated approval from the US Food and Drug Administration (FDA) in November 1995. The drug is manufactured and distributed by Glaxo Wellcome. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI). In combination with other antiretroviral agents, lamivudine can be effective in suppressing viral replication. The drug is also effective in suppressing the Hepatitis B virus (although in a different formulation, Zeffix).

Guidelines classification. The Panel on Clinical Practices for the Treatment of HIV Infection classifies lamivudine as "strongly recommended" when used with stavudine (Zerit) or zidovudine (Retrovir).

Dose. The recommended lamivudine dosing for adults and adolescents (12 to 16 years of age) is 150 mg twice a day. For adults with low body weights (less than 110 lb) the recommended dose is 2 mg/kg twice a day. Dosing should be adjusted in patients with kidney problems (based on creatinine clearance).

Food restrictions. Lamivudine can be taken with or without a meal.

Storage. Tablets should be stored between 36 [degrees] and 86 [degrees] F in a tightly closed container. The solution should also be kept in a tightly closed container and stored between 36 [degrees] and 77 [degrees] F

Side effects and toxicity. Lactic acidosis and severe hepatomegaly (enlarged liver) with steatosis (fatty liver) are rare, but potentially fatal, and have been associated with NRTI use. Lamivudine is considered to have minimal toxicity and few side effects. Some reported side effects include headache, fatigue and nausea.

Drug interactions. There are no known clinically significant drug interactions with lamivudine.

Resistance and cross-resistance. Lamivudine resistance is associated with a mutation at position 184. When used as monotherapy lamivudine results in rapid and uniform resistance, usually within a few weeks. The mutation at position 184 results in 1000-fold resistance to lamivudine. Early reports indicated that the 184 mutation could improve susceptibility to zidovudine; other reports have suggested that lamivudine resistance confers increased fidelity to the reverse transcriptase enzyme and makes the virus less fit or less pathogenic. The validity of these reports has yet to be proven, but their mere existence and the fact that lamivudine has very few side effects and toxicities has led to the widespread use of the drug even in the presence of clear-cut resistance. A mutation at position 333 confers resistance to both zidovudine and lamivudine. A mutation at position 151 is associated with resistance to the entire NRTI class. An insertion at position 69 can also lead to broad NRTI resistance.

Clinical data. Registrational studies for lamivudine noted its efficacy when combined with zidovudine (Retrovir), but subsequent data indicate more potent effects when used in combination with other drug classes (see table on page 5). Studies of patients failing highly active antiretroviral therapy (HAART) with the combination of indinavir (Crixivan)/ zidovudine/ lamivudine report that virologic rebound is at least initially associated with the mutation at position 184 and resistance to lamivudine.

Patient assistance. For those who qualify, Glaxo Wellcome offers a patient assistance program. For more information, call 800.722.9294.

COPYRIGHT 2000 The Center for AIDS: Hope & Remembrance Project
COPYRIGHT 2000 Gale Group

Return to Lamivudine
Home Contact Resources Exchange Links ebay